Sexual dysfunctions are a category of clinical disorders affecting sexual response or producing pain associated with sexual activity. DSM-5 organizes them by phase of the sexual response cycle and by specific complaint: desire disorders (hypoactive sexual desire), arousal disorders (erectile disorder in men, female sexual interest/arousal disorder), orgasm disorders (premature ejaculation, delayed ejaculation, female orgasmic disorder), pain disorders (genito-pelvic pain/penetration disorder).
The clinical reality: sexual dysfunctions are common (affecting 30-50% of adults at some point), substantially impact quality of life and relationships, and are often hidden from clinical attention because of patient discomfort discussing them. Direct inquiry catches what spontaneous reporting misses.
The multifactorial workup:
Medical/medication contributors — diabetes (vascular and neuropathic effects on arousal), cardiovascular disease, hypogonadism, thyroid disease, neurological conditions, postoperative changes (particularly prostatectomy, gynecologic surgery), medications (SSRIs and SNRIs particularly — affecting 30-70% of patients on serotonergic antidepressants; antipsychotics; antihypertensives; opioids).
Psychological contributors — depression, anxiety (performance anxiety particularly), trauma history, body image issues, religious or cultural beliefs producing conflict.
Relational contributors — relationship conflict, decreased intimacy, mismatched libidos, communication problems, infidelity, illness affecting partner.
Substance use — alcohol affects arousal and orgasm; opioids reduce libido and produce hypogonadism; chronic cannabis use has variable effects; stimulants acutely enhance but chronically impair.
The medication-induced sexual dysfunction problem: SSRIs cause sexual side effects (delayed orgasm, anorgasmia, reduced libido, erectile difficulty) in 30-70% of patients. Often the patient does not volunteer the symptom; clinicians often don't ask directly; the side effect is undertreated. Strategies: (1) reduce dose if depression well-controlled; (2) switch to bupropion (no sexual side effects); (3) add bupropion to existing SSRI for augmentation; (4) PDE-5 inhibitor for ED component; (5) drug holidays for short-acting SSRIs (not effective for fluoxetine due to long half-life); (6) consider less-serotonergic alternatives like vortioxetine or vilazodone.
Specific treatments by diagnosis:
Erectile disorder: PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) — highly effective for vascular and most psychogenic erectile disorder. Vacuum devices, intracavernosal injection, surgical implants for severe cases.
Premature ejaculation: SSRIs (paroxetine, sertraline, dapoxetine specifically) delay ejaculation; topical lidocaine; behavioral techniques (stop-start, squeeze).
Female sexual interest/arousal disorder: flibanserin (Addyi) — daily 5-HT1A agonist/2A antagonist for premenopausal women. Bremelanotide (Vyleesi) — on-demand melanocortin agonist injection. Limited efficacy; substantial side effects. Couples therapy, hormonal evaluation, address contributing factors often more impactful.
Genito-pelvic pain: pelvic floor physical therapy, behavioral therapy, sometimes topical lidocaine, address gynecologic conditions (vulvodynia, vaginismus, endometriosis).
Couples and sex therapy often more impactful than pharmacology alone. Address relationship dynamics, communication, intimacy patterns. Sensate focus exercises rebuild physical connection in disconnected couples.
When you encounter sexual dysfunction, systematic workup is the most consequential clinical move. Identify contributing factors, address each, often produces substantial improvement. Sexual function affects quality of life and relationships profoundly — it deserves attention.